Status:
COMPLETED
A Study of Nivolumab in Patients With Head and Neck Cancer.
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck
Eligibility:
All Genders
18+ years
Brief Summary
A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy
Eligibility Criteria
Inclusion
- Diagnosis of Squamous Cell Carcinoma Head and Neck (SCCHN) patients progressing on or after platinum-based therapy.
- Diagnosis of SCCHN has been confirmed by histology or cytology (either at initial diagnosis or any time later during the course of the disease)
- Treatment decision to initiate a treatment with nivolumab for the first time for the treatment of SCCHN (according to the label approved in France) has already been taken
Exclusion
- Patients previously treated with Nivolumab, Ipilimumab, or any other antibody or drug specifically targeting T-Cell Co stimulation or immune Checkpoint pathway.
- Patients currently included in an interventional clinical trial for their SCCHN.
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
June 26 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 8 2024
Estimated Enrollment :
502 Patients enrolled
Trial Details
Trial ID
NCT04050761
Start Date
June 26 2019
End Date
July 8 2024
Last Update
July 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Paris, Île-de-France Region, France, 75005